221 related articles for article (PubMed ID: 10480007)
1. Designer estrogens: breast cancer benefit, remaining questions.
Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
[No Abstract] [Full Text] [Related]
2. Tamoxifen for prevention of breast cancer.
Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486
[No Abstract] [Full Text] [Related]
3. Ductal carcinoma in situ.
Venniyoor A
Aust Fam Physician; 2006 May; 35(5):278-9; author reply 279. PubMed ID: 16708448
[No Abstract] [Full Text] [Related]
4. Anti-estrogens come of age: a pioneer looks back.
Nelson NJ
J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
[No Abstract] [Full Text] [Related]
5. Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
Park L; Evans MF
Can Fam Physician; 1999 May; 45():1191-3. PubMed ID: 10349062
[No Abstract] [Full Text] [Related]
6. [Is low-dose tamoxifen an effective therapy for breast carcinoma in situ?].
Ivanova OA; Zhil'tsova EK; Barash NIu; Ivanov VG; Ermachenkova AM
Vopr Onkol; 2011; 57(5):601-3. PubMed ID: 22238929
[No Abstract] [Full Text] [Related]
7. Until there's more information, caution advised in using tamoxifen or raloxifene for breast cancer prevention.
Mayo Clin Health Lett; 1998 Jul; 16(7):4. PubMed ID: 9663019
[No Abstract] [Full Text] [Related]
8. Using SERMS for treating postmenopausal symptoms.
Brockie J
Community Nurse; 1999 Jan; 4(12):30-1. PubMed ID: 10326399
[No Abstract] [Full Text] [Related]
9. Designer estrogens.
Jordan VC
Sci Am; 1998 Oct; 279(4):60-7. PubMed ID: 9768522
[No Abstract] [Full Text] [Related]
10. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
[TBL] [Abstract][Full Text] [Related]
11. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
12. STAR trial reports.
Eur J Cancer; 2006 Aug; 42(12):1694. PubMed ID: 16998956
[No Abstract] [Full Text] [Related]
13. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
Yen TW; Kuerer HM; Ottesen RA; Rouse L; Niland JC; Edge SB; Theriault RL; Weeks JC
J Clin Oncol; 2007 Aug; 25(22):3251-8. PubMed ID: 17577019
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of breast cancer: recommendations and rationale.
Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
[No Abstract] [Full Text] [Related]
16. [Current trends in prevention and therapy of postmenopausal osteoporosis].
Rossi G
Recenti Prog Med; 1998 Jun; 89(6):288. PubMed ID: 9658894
[No Abstract] [Full Text] [Related]
17. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Jordan VC
J Natl Cancer Inst; 1998 Jul; 90(13):967-71. PubMed ID: 9665143
[No Abstract] [Full Text] [Related]
18. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen in cancer therapy: minireview.
Novotny L; Rauko P; Vachálková A; Peterson-Biggs M
Neoplasma; 2000; 47(1):3-7. PubMed ID: 10870680
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen debate hinges on whose risk is high enough.
Reynolds T
J Natl Cancer Inst; 1998 Oct; 90(19):1428-30. PubMed ID: 9776407
[No Abstract] [Full Text] [Related]
[Next] [New Search]